ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
When Ipsen announced last week that it wanted in on Exelixis’ Cabometyx for thyroid cancer, the company pegged that move to the oncology drug’s promising late-stage trial results. Now, Exelixis is offering up more details of that very trial. For a phase 3 study up for presentation at the virtual American Society of Clinical Oncology meeting, investigators… Read More »